Treating EGFR-mutant nonsmall cell lung cancer is no longer a one-size-fits-all approach.
作者信息
Antrim Lauren J, Malhotra Jyoti
机构信息
City of Hope Comprehensive Cancer Center, Duarte, California, USA.
出版信息
CA Cancer J Clin. 2025 Sep-Oct;75(5):373-375. doi: 10.3322/caac.70027. Epub 2025 Aug 4.
Abstract
摘要
相似文献
1
Treating EGFR-mutant nonsmall cell lung cancer is no longer a one-size-fits-all approach.治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌不再是一种一刀切的方法。
CA Cancer J Clin. 2025 Sep-Oct;75(5):373-375. doi: 10.3322/caac.70027. Epub 2025 Aug 4.
3
Cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer.奥希替尼作为 EGFR 突变晚期非小细胞肺癌一线治疗的成本效益分析。
Future Oncol. 2024;20(34):2661-2670. doi: 10.1080/14796694.2024.2395803. Epub 2024 Sep 20.
4
Depression and inflammation among epidermal growth factor receptor (EGFR) mutant nonsmall cell lung cancer patients.表皮生长因子受体（EGFR）突变型非小细胞肺癌患者的抑郁和炎症。
Psychooncology. 2019 Jul;28(7):1461-1469. doi: 10.1002/pon.5097. Epub 2019 May 15.
5
CRISPR-dCas9-Mediated PTEN Activation via Tumor Cell Membrane-Coated Nanoplatform Enhances Sensitivity to Tyrosine Kinase Inhibitors in Nonsmall Cell Lung Cancer.通过肿瘤细胞膜包被的纳米平台进行CRISPR-dCas9介导的PTEN激活可增强非小细胞肺癌对酪氨酸激酶抑制剂的敏感性
ACS Appl Mater Interfaces. 2025 Mar 5;17(9):13605-13616. doi: 10.1021/acsami.4c21740. Epub 2025 Feb 20.
6
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.国际肺癌研究协会/美国胸科学会/欧洲呼吸学会国际多学科肺腺癌分类。
J Thorac Oncol. 2011 Feb;6(2):244-85. doi: 10.1097/JTO.0b013e318206a221.
7
EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.表皮生长因子受体酪氨酸激酶抑制剂与紫杉烷类药物治疗非小细胞肺癌患者的疗效比较：一项遵循PRISMA规范的系统评价及Meta分析与Meta回归分析
Medicine (Baltimore). 2016 Dec;95(50):e5601. doi: 10.1097/MD.0000000000005601.
8
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.辅助性表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）用于治疗已切除的Ⅰ至Ⅲ期非小细胞肺癌且伴有EGFR突变的患者。
Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.
9
Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?胃肠道管状非小细胞型高级别神经内分泌癌是一种独特的疾病实体吗？
Am J Surg Pathol. 2008 May;32(5):719-31. doi: 10.1097/PAS.0b013e318159371c.
10
The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer.在第三代 EGFR-TKIs 治疗进展后的 EGFR 突变型晚期非小细胞肺癌中添加安罗替尼的疗效和安全性。
Anticancer Drugs. 2024 Jun 1;35(5):433-439. doi: 10.1097/CAD.0000000000001575. Epub 2024 Feb 22.
本文引用的文献
1
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.表皮生长因子受体（EGFR）突变型非小细胞肺癌患者的个性化护理：从早期到晚期疾病管理的全程指引
CA Cancer J Clin. 2025 Sep-Oct;75(5):387-409. doi: 10.3322/caac.70024. Epub 2025 Jul 17.
2
Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.使用静脉注射氨万他单抗预防输液相关反应——SKIPPirr 2期研究结果：简要报告
J Thorac Oncol. 2025 Jun;20(6):809-816. doi: 10.1016/j.jtho.2025.01.018. Epub 2025 Jan 24.
3
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.奥希替尼用于不可切除的 III 期表皮生长因子受体突变非小细胞肺癌根治性放化疗后：III 期 LAURA 研究的中枢神经系统疗效及远处进展分析
Ann Oncol. 2024 Dec;35(12):1116-1125. doi: 10.1016/j.annonc.2024.08.2243. Epub 2024 Sep 16.
4
Amivantamab plus Lazertinib in Previously Untreated -Mutated Advanced NSCLC.Amivantamab 联合 Lazertinib 治疗未经治的 - 突变型晚期 NSCLC。
N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26.
5
A Real-World Study of Patient Characteristics and Clinical Outcomes in Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice.一线奥希替尼治疗突变型肺癌患者特征及临床结局的真实世界研究：将 FLAURA 试验结果扩展至常规临床实践
Cancers (Basel). 2024 Mar 7;16(6):1079. doi: 10.3390/cancers16061079.
6
Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.奥希替尼对比含铂化疗用于 - 突变型晚期 NSCLC。
N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.
7
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.ADAURA研究中术后化疗的使用情况及结果：奥希替尼作为切除的EGFR突变型非小细胞肺癌的辅助治疗
J Thorac Oncol. 2022 Mar;17(3):423-433. doi: 10.1016/j.jtho.2021.10.014. Epub 2021 Nov 2.
8
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for -mutated resectable non-small-cell lung cancer: NeoADAURA.奥希替尼新辅助治疗联合/不联合化疗对比单纯化疗用于可切除 - 突变型非小细胞肺癌：NeoADAURA 研究。
Future Oncol. 2021 Nov;17(31):4045-4055. doi: 10.2217/fon-2021-0549. Epub 2021 Jul 19.
9
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
10
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.非小细胞肺癌患者中表皮生长因子受体（EGFR）突变的患病率：一项系统评价和荟萃分析。
Oncotarget. 2016 Nov 29;7(48):78985-78993. doi: 10.18632/oncotarget.12587.
Zotero 插件